Please assess the completion status of the following clinical trial:

Trial Title: Study of Brexpiprazole as Adjunctive Treatment of Sleep Disturbances in Patients With Major Depressive Disorder

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria - at Screening:~* The patient has a Major Depressive Episode (MDE) associated to Major Depressive Disorder (MDD), diagnosed according to Diagnostic and Statistical Manual of Mental Disorders, 4th edition, Text Revision (DSM-IV-TR™). The current MDE should be confirmed using the Mini International Neuropsychiatric Interview (MINI).~* The patient has an inadequate response to at least one antidepressant treatment (including the treatment the patient is taking at screening) in the current MDE, as documented by self-report as less than a pre-defined response on the Massachusetts General Hospital Antidepressant Treatment Response Questionnaire (ATRQ).~* The patient has a pre-defined Montgomery Aasberg Depression Rating Scale (MADRS) total score, and a pre-defined Clinical Global Impression - Severity of Illness (CGI-S) score at screening, and has had the current MDE for ≥10 weeks.~* The patient is currently treated for the current MDE with an adequate selective serotonin reuptake inhibitor (SSRI) or a serotonin-norepinephrine reuptake inhibitor (SNRI) antidepressant treatment for ≥6 weeks, at the same dosage for ≥2 weeks.~* The patient has sleep disturbances (difficulty falling asleep and/or difficulty staying asleep and/or problem waking up too early) confirmed by a pre-defined Insomnia Severity Index (ISI) score.~* The patient agrees to protocol-defined use of effective contraception.~Entry Criteria to Treatment Period (Baseline Visit):~* The patient still fulfils DSM-IV-TR™ criteria for MDE.~* The patient received the same SSRI or SNRI antidepressant treatment at adequate dose during the entire lead-in period.~* The patient has a pre-defined MADRS total score.~* The patient's improvement in the MADRS total score is a pre-defined percentage compared to screening.~* The patient has a pre-defined Clinical Global Impression - Global Improvement (CGI-I) score.~* The patient has sleep disturbances (difficulty falling asleep and/or difficulty staying asleep and/or problem waking up too early) confirmed by a pre-defined ISI score.~* The patient has sleep disturbances confirmed by pre-defined Latency to Persistent Sleep (LPS) and pre-defined Sleep Efficiency (SE).~Exclusion Criteria:~- The patient is, in the investigator's opinion, unlikely to comply with the protocol or is unsuitable for any reason.~Other inclusion and exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Brexpiprazole (Type: EXPERIMENTAL): Brexpiprazole adjunct to open-label treatment with a commercially available antidepressant treatment (ADT)

Based on this trial design, predict the completion outcome and termination type (if applicable).